HRAS and hepatocellular carcinoma: The findings indicated that point mutations in the KRAS gene, but not mutations in the NRAS, HRAS, BRAF, PIK3CA, PIK3R1 and PTEN genes, at the somatic level contribute to the abnormal activation of the RAS/RAF and PI3K/PTEN pathways in HCC.